Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.

Huang L, Wong CC, Mackenzie GG, Sun Y, Cheng KW, Vrankova K, Alston N, Ouyang N, Rigas B.

BMC Cancer. 2014 Feb 28;14:141. doi: 10.1186/1471-2407-14-141.

2.

Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate.

Murray OT, Wong CC, Vrankova K, Rigas B.

Int J Oncol. 2014 Feb;44(2):521-9. doi: 10.3892/ijo.2013.2190. Epub 2013 Nov 27.

3.

A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.

Mackenzie GG, Bartels LE, Xie G, Papayannis I, Alston N, Vrankova K, Ouyang N, Rigas B.

Neoplasia. 2013 Oct;15(10):1184-95.

4.

Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice.

Mackenzie GG, Huang L, Alston N, Ouyang N, Vrankova K, Mattheolabakis G, Constantinides PP, Rigas B.

PLoS One. 2013 May 1;8(5):e61532. doi: 10.1371/journal.pone.0061532. Print 2013.

5.

Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins.

Zhang Y, Gu Y, Lee HM, Hambardjieva E, Vranková K, Golub LM, Johnson F.

Curr Med Chem. 2012;19(25):4348-58.

PMID:
22830350
6.

Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.

Zhu R, Cheng KW, Mackenzie G, Huang L, Sun Y, Xie G, Vrankova K, Constantinides PP, Rigas B.

Pharm Res. 2012 Nov;29(11):3090-101. doi: 10.1007/s11095-012-0801-x. Epub 2012 Jun 22.

7.

Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.

Sun Y, Rowehl LM, Huang L, Mackenzie GG, Vrankova K, Komninou D, Rigas B.

Breast Cancer Res. 2012 Jan 31;14(1):R20.

8.

Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

Huang L, Mackenzie GG, Sun Y, Ouyang N, Xie G, Vrankova K, Komninou D, Rigas B.

Cancer Res. 2011 Dec 15;71(24):7617-27. doi: 10.1158/0008-5472.CAN-11-2349. Epub 2011 Oct 24.

9.

Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.

Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B.

Cancer Prev Res (Phila). 2011 Jul;4(7):1052-60. doi: 10.1158/1940-6207.CAPR-11-0067. Epub 2011 Apr 4.

10.

On the selective N-methylation of BOC-protected amino acids.

Malkov AV, Vranková K, Cerný M, Kocovský P.

J Org Chem. 2009 Nov 6;74(21):8425-7. doi: 10.1021/jo9016293.

PMID:
19821609
11.

Asymmetric reduction of imines with trichlorosilane, catalyzed by sigamide, an amino acid-derived formamide: scope and limitations.

Malkov AV, Vranková K, Stoncius S, Kocovský P.

J Org Chem. 2009 Aug 21;74(16):5839-49. doi: 10.1021/jo900561h.

PMID:
19530670
12.

Dynamic kinetic resolution in the asymmetric synthesis of beta-amino acids by organocatalytic reduction of enamines with trichlorosilane.

Malkov AV, Stoncius S, Vranková K, Arndt M, Kocovský P.

Chemistry. 2008;14(27):8082-5. doi: 10.1002/chem.200801244. No abstract available.

PMID:
18666274

Supplemental Content

Loading ...
Support Center